The triple monoaminergic reuptake inhibitor DOV 216,303 has antidepressant effects in the rat olfactory bulbectomy model and lacks sexual side effects

European Neuropsychopharmacology

Volumn 18, Issue 12, 2008, Pages 908-916

  Breuer, M E ^a   Chan, J S W ^a   Oosting, R S ^a   Groenink, L ^a   Korte, S M ^a   Campbell, U ^c   Schreiber, R ^c   Hanania, T ^b   Snoeren, E M S ^a   Waldinger, M ^a   Olivier, B ^a,b,d  

^a UTRECHT UNIVERSITY   (Netherlands)

^b PSYCHOGENICS INC   (United States)

^c SUNOVION PHARMACEUTICALS INC   (United States)

^d YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antidepressant; Depression; Olfactory bulbectomy; Rats; Sexual behavior; TUI

Indexed keywords

1 (3,4 DICHLOROPHENYL) 3 AZABICYCLO[3.1.0]HEXANE; ANTIDEPRESSANT AGENT; DOV 216303; IMIPRAMINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; DEPRESSION; DRUG EFFECT; DRUG EFFICACY; FEMALE; HYPERACTIVITY; LONG TERM CARE; MALE; NONHUMAN; OLFACTORY BULBECTOMY; OPEN FIELD BEHAVIOR; PRIORITY JOURNAL; RAT; SEXUAL BEHAVIOR;

ANIMALS; ANTIDEPRESSIVE AGENTS; AZA COMPOUNDS; BEHAVIOR, ANIMAL; BICYCLO COMPOUNDS, HETEROCYCLIC; BODY WEIGHT; DEPRESSION; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; EJACULATION; EXPLORATORY BEHAVIOR; MALE; OLFACTORY BULB; PAROXETINE; RATS; RATS, SPRAGUE-DAWLEY; REACTION TIME; STATISTICS, NONPARAMETRIC;

EID: 53649086029     PISSN: 0924977X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2008.07.011     Document Type: Article

References (48)

1. Bertaina-Anglade V., LaRochelle C.D., and Scheller D.K. Antidepressant properties of rotigotine in experimental models of depression. Eur. J. Pharmacol. 548 1-3 (2006) 106-114
2. Berton O., and Nestler E.J. New approaches to antidepressant drug discovery: beyond monoamines. Nat. Rev., Neurosci. 7 (2006) 137-151
3. Breuer M.E., Groenink L., Oosting R.S., Westenberg H.G.M., and Olivier B. Long-term behavioral changes after cessation of chronic anti-depressant treatment in olfactory bulbectomized rats. Biol. Psychiatry 61 (2007) 990-995
4. Brown A.S., and Gershon S. Dopamine and depression. J. Neural Transm. Gen. Sect. 91 2-3 (1993) 75-109
5. Chambliss H.O., van Hoomissen J.D., Holmes P.V., Bunnell B.N., and Dishman R.K. Effects of chronic activity wheel running and imipramine on masculine copulatory behavior after olfactory bulbectomy. Physiol. Behav. 82 4 (2004) 593-600
6. Chan J., Olivier B., de Jong T., Snoeren E., Kooijman E., van Hasselt F., Limpens J., Kas M., Waldinger M., and Oosting R. Translational research into sexual disorders: pharmacology and genomics. Eur. J. Pharmacol. 585 2-3 (2007) 426-435
7. Clayton A.H., Pradko J.F., Croft H.A., Montano C.B., Leadbetter R.A., Bolden-Watson C., Bass K.I., Donahue R.M., Jamerson B.D., and Metz A. Prevalence of sexual dysfunction among newer antidepressants. J. Clin. Psychiatry 63 (2002) 357-366
8. Clayton A.H., Warnock J.K., Kornstein S.G., Pinkerton R., Sheldon-Keller A., and McGarvey E.L. A placebo-controlled trial of bupropion SR as an antidote for selective serotonin reuptake inhibitor-induced sexual side effects. J. Clin. Psychiatry 65 (2004) 62-67
9. Cryan J.F., McGrath C., Leonard B.E., and Norman T.C. Onset of the effects of the 5-HT1A agonist, WAY-100635, alone, and in combination with paroxetine, on olfactory bulbectomy and 8-OH-DPAT-induced changes in the rat. Pharmacol. Biochem. Behav. 63 2 (1999) 333-338
10. D'Aquila P.S., Panin F., and Serra G. Long-term imipramine withdrawal induces a depressive-like behaviour in the forced swimming test. Eur. J. Pharmacol. 492 (2004) 61-63
11. De Jong T.R., Pattij T., Veening J.G., Dederen P.J.W.C., Waldinger M.D., Cools A.R., and Olivier B. Citalopram combined with WAY100635 inhibits ejaculation and ejaculation-related Fos immunoreactivity. Eur. J. Pharmacol. 509 (2005) 49-59
12. De Jong T.R., Pattij T., Veening J.G., Waldinger M.D., Cools A.R., and Olivier B. Effects of chronic selective serotonin reuptake inhibitors on 8-OH-DPAT-induced facilitation of ejaculation in rats: comparison of fluvoxamine and paroxetine. Psychopharmacology 179 (2005) 509-515
13. Eriksson E. Antidepressant drugs: does it matter if they inhibit the reuptake of noradrenaline or serotonin?. Acta Psychiatr. Scand. S402 (2000) 12-17
14. Fava M., and Rankin M. Sexual functioning and SSRIs. J. Clin. Psychiatry 63 Supp; 5 (2002) 13-16 discussion 23-25
15. Foley K.F., DeSanty K.P., and Kast R.E. Bupropion: pharmacology and therapeutic applications. Expert Rev. Neurother. 6 (2006) 1249-1265
16. Gershon A.A., Vishne T., and Grunhaus L. Dopamine D2-like receptors and the antidepressant response. Biol. Psychiatry 61 2 (2007) 145-153
17. Gitlin M., Suri R., Altshuler L., Zuckerbrow-Miller J., and Fairbanks L. Bupropion-sustained release as a treatment for SSRI-induced sexual side effects. J. Sex Marital Ther. 28 (2002) 131-138
18. Grecksch G., Zhou D., Franke C., Schroder U., Sabel B., Becker A., et al. Influence of olfactory bulbectomy and subsequent imipramine treatment on 5-hydroxytryptaminergic presynapses in the rat frontal cortex: behavioral correlates. Br. J. Pharmacol. 122 8 (1997) 1725-1731
19. Hull E.M., Muschamp J.W., and Sato S. Dopamine and serotonin: influences on male sexual behavior. Physiol. Behav. 83 (2004) 291-307
20. Kelly J., Wrynn A., and Leonard B. The olfactory bulbectomized rat as a model of depression: an update. Pharmacol. Ther. 74 3 (1997) 299-316
21. Klerman G.L., and Cole J. Clinical pharmacology of imipramine and related antidepressant compounds. Pharmacol. Rev. 17 (1967) 101-141
22. Lemke M.R., Brecht H.M., Koester J., Kraus P.H., and Reichmann H. Anhedonia, depression and motor functioning in Parkinson's disease during treatment with pramipexole. J. Neuropsychiatry Clin. Neurosci. 17 2 (2005) 214-220
23. Manji H.K., Drevets W.C., and Charney D.S. The cellular neurobiology of depression. Nat. Med. 7 (2001) 541-547
24. Masini C.V., Holmes P.V., Freeman K.G., Maki A.C., and Edwards G.L. Dopamine overflow is increased in olfactory bulbectomized rats: an in-vivo microdialysis study. Physiol. Behav. 81 1 (2004) 111-119
25. Mos J., Mollet I., Tolboom J.T.B.M., Waldinger M.D., and Olivier B. A comparison of the different serotonin reuptake blockers on sexual behavior of the male rat. Eur. Neuropsychopharmacol. 9 (1999) 123-135
26. Naranjo C.A., Tremblay L.K., and Busto U.E. The role of the brain reward system in depression. Prog. Neuropsychopharmacol. Biol. Psychiatry 25 4 (2001) 781-823
27. Nestler E.J., and Carlezon Jr. W.A. The mesolimbic dopamine reward circuit in depression. Biol. Psychiatry 15 (2006) 1151-1159
28. Nestler E.J., Barrot M., DiLeone R.J., Eisch A.J., Gold S.J., and Monteggia L.M. Neurobiology of depression. Neuron 34 (2002) 13-25
29. Olivier B., Chan J., Pattij T., de Jong T.R., Oosting R.S., Veening J., and Waldinger M.D. Psychopharmacology of male rat sexual behavior: modeling human sexual dysfunctions?. Int. J. Impot. Res. 18 (2006) S14-S23
30. Pattij T., Olivier B., and Waldinger M.D. Animal models of ejaculatory behavior. Curr. Pharm. Des. 11 31 (2005) 4069-4077
31. Peeters M., and Giuliano F. Central neurophysiology and dopaminergic control of ejaculation. Neuro. Biobehav. Rev. 32 (2007) 438-453
32. Schechter L.E., Ring R.H., Beyer C.E., Hughes Z.A., Khawaja X., Malberg J.E., and Rosenzweig-Lipson S. Innovative approaches for the development of antidepressant drugs: current and future strategies. NeuroRx 2 4 (2005) 590-611
33. Shaw A.M., Boules M., Zhang Y., Williams K., Robinson J., Carlier P.R., and Richelson E. Antidepressant-like effects of novel triple reuptake inhibitors, PRC024 and PRC050. Eur. J. Pharmacol. 555 (2007) 30-36
34. Sheline Y.I. Neuro-imaging studies of mood disorder effects on the brain. Biol. Psychiatry 54 3 (2003) 338-352
35. Skolnick P., Popik P., Janowsky A., Beer B., and Lippa A. Antidepressant-like actions of DOV 21,947: a 'triple' reuptake inhibitor. Eur. J. Pharmacol. 461 (2003) 99-104
36. Skolnick P., Krieter P., Tizzano J., Popik P., Czobor P., and Lippa A. Preclinical and clinical pharmacology of DOV 216,303, a 'triple' reuptake inhibitor. CNS Drug Rev. 12 (2006) 123-134
37. Slotkin T.A., Cousins M.M., Tate C.A., and Seidler F.J. Serotonergic cell signaling in an animal model of aging and depression: olfactory bulbectomy elicits different adaptations in brain regions of young adult vs. aging rats. Neuropsychopharmacology 30 1 (2005) 52-57
38. Song C., and Leonard B.E. The olfactory bulbectomized rat as a model of depression. Neurosci. Biobehav. Rev. 29 (2005) 627-649
39. Stahl S.M., Pradko J.F., Haight B.R., Modell J.G., Rockett C.B., and Learned-Coughlis S. A review of the neuropharmacology of bupropion, a dual norepinephrine and dopamine reuptake inhibitor. Primary Care Companion J. Clin. Psychiatry 6 (2004) 159-166
40. Thase M.E., Clayton A.H., Haight B.R., Thompson A.H., Modell J.G., and Johnston J.A. A double-blind comparison between bupropion XL and venlafaxine XR: sexual functioning, antidepressant efficacy, and tolerability. J. Clin. Psychopharmacol. 26 (2006) 482-488
41. Tizzano J.P., Stribling D.S., Perez-Tilve D., Strack A., Frassetto A., Chen R.Z., Fong T.M., Shearman L., Krieter P.A., Tschop M.H., Skolnick P., and Basile A.S. The triple uptake inhibitor (1R, 5S)-(+)-1-(3,4-Dichlorophenyl)-3-azabicyclo[3.1.0] hexane hydrochloride (DOV 21947) reduces body weight and plasma triglycerides in rodent models of diet-induced obesity. J. Pharm. Exp. Ther. 324 (2008) 1111-1126
42. Uzunova V., Wrynn A.S., Kinnunen A., Ceci M., Kohler C., and Uzunov D.P. Chronic antidepressants reverse cerebrocortical allopregnanolone decline in the olfactory-bulbectomized rat. Eur. J. Pharmacol. 486 (2004) 31-34
43. Van der Stelt H.M., Breuer M.E., Olivier B., and Westenberg H.G. Permanent deficits in serotonergic functioning of olfactory bulbectomized rats: an in vivo microdialysis study. Biol. Psychiatry 57 (2005) 1061-1067
44. Waldinger M.D., Van de Plas A., Pattij T., van Oorschot R., Coolen L.M., Veening J., and Olivier B. The selective serotonin re-uptake inhibitors fluvoxamine and paroxetine differ in sexual inhibitory effects after chronic treatment. Psychopharmacology 160 (2002) 283-289
45. Wieronska J.M., Papp M., and Pilc A. Effects of anxiolytic drugs on some behavioral consequences in olfactory bulbectomized rats. Pol. J. Pharmacol. 53 (2001) 517-525
46. Willner P. Dopamine and depression: a review of recent evidence. I. Empirical studies. Brain Res. 287 3 (1983) 211-224
47. Willner P., Hale A.S., and Argyropoulos S. Dopaminergic mechanism of antidepressant action in depressed patients. J. Affect. Discord. 86 (2005) 37-45
48. Zisook S., Rush A.J., Haight B.R., Clines D.C., and Rockett C.B. Use of bupropion in combination with serotonin reuptake inhibitors. Biol. Psychiatry 59 (2006) 203-210